Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PASG
stocks logo

PASG

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-2.798
-30.05%
--
--
-1.840
-63.2%
--
--
-1.740
-41.22%
Estimates Revision
The market is revising No Change the revenue expectations for Passage Bio, Inc. (PASG) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 27.90%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+27.90%
In Past 3 Month
Wall Street analysts forecast PASG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PASG is 40.33 USD with a low forecast of 21.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast PASG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PASG is 40.33 USD with a low forecast of 21.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.183
sliders
Low
21.00
Averages
40.33
High
68.00
Current: 9.183
sliders
Low
21.00
Averages
40.33
High
68.00
Lucid Capital
Elemer Piros
Buy
initiated
$68
2025-11-24
Reason
Lucid Capital
Elemer Piros
Price Target
$68
2025-11-24
initiated
Buy
Reason
Lucid Capital analyst Elemer Piros initiated coverage of Passage Bio with a Buy rating and $68 price target. Passage Bio, which has developed a one-time gene therapy treatment, PBFT02, to correct certain genetic defects that lead to frontotemporal dementia is "at the forefront of treating dementia with one-time gene therapies," the analyst tells investors.
Canaccord
Buy
downgrade
$260 -> $67
2025-08-14
Reason
Canaccord
Price Target
$260 -> $67
2025-08-14
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Passage Bio to $67 from $260 and keeps a Buy rating on the shares. The firm decreased its peak penetration and probability of success assumptions given the evolving competitive landscape and to await more details on the safety profile.
Guggenheim
Debjit Chattopadhyay
Buy
downgrade
$4 -> $2
2025-05-20
Reason
Guggenheim
Debjit Chattopadhyay
Price Target
$4 -> $2
2025-05-20
downgrade
Buy
Reason
Guggenheim analyst Debjit Chattopadhyay lowered the firm's price target on Passage Bio to $2 from $4 and keeps a Buy rating on the shares after updating the firm's models following Q1 results. The firm revised its 2025 projections to reflect the 55% workforce reduction in January, leading to lower R&D and SG&A expense estimates, adding that it believes Passage will need to raise capital and increase its share count in the near future.
Chardan Capital
Geulah Livshits
Strong Buy
Maintains
$7 → $6
2025-03-04
Reason
Chardan Capital
Geulah Livshits
Price Target
$7 → $6
2025-03-04
Maintains
Strong Buy
Reason
Chardan lowered the firm's price target on Passage Bio to $6 from $7 and keeps a Buy rating on the shares. The firm updated the company's model for the Q4 report. Data from patients treated with dose 1 of PBFT02 continue to look encouraging in frontotemporal dementia with GRN mutations, with patient dosing underway for a lower dose, the analyst tells investors in a research note. The firm sees upcoming catalysts for the shares, including updated data from the trial in the second half of 2025.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Passage Bio Inc (PASG.O) is -1.11, compared to its 5-year average forward P/E of -1.65. For a more detailed relative valuation and DCF analysis to assess Passage Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.65
Current PE
-1.11
Overvalued PE
0.21
Undervalued PE
-3.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.05
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.53
Undervalued EV/EBITDA
-1.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.64
Current PS
0.00
Overvalued PS
7.64
Undervalued PS
-4.36
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PASG News & Events

Events Timeline

(ET)
2025-11-10
16:50:10
Passage Bio Reports Q3 Earnings Per Share of $2.44, Below Consensus Estimate of $2.97
select
2025-08-12 (ET)
2025-08-12
07:09:59
Passage Bio expects cash to fund operations into Q1 of 2027
select
2025-08-12
07:09:42
Passage Bio reports Q2 EPS ($2.96) vs ($5.09) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-12TipRanks
Top Analysts Recommend 3 Biotech Stocks to Purchase Now, 11/12/2025

  • Top Biotech Stocks: Recent analyst updates highlight three biotech companies—Passage Bio, BioNTech, and Upstream Bio—that have received Strong Buy ratings from top Wall Street analysts, indicating solid upside potential.

  • Passage Bio (PASG): This clinical-stage biotech focuses on gene therapies for rare brain diseases, with a maintained Buy rating and a price target of $21, suggesting a potential upside of about 400%.

  • BioNTech (BNTX): Known for its mRNA technology in immunotherapies and vaccines, BioNTech has a Buy rating with a price target of $151, indicating a potential upside of approximately 29.37%.

  • Upstream Bio, Inc. (UPB): This company develops therapies for respiratory and inflammatory diseases, holding a Buy rating with a price target suggesting a potential upside of about 215.4%.

[object Object]
Preview
9.5
11-11NASDAQ.COM
PASSAGE BIO, INC. Reports Reduced Q3 Loss, Surpassing Expectations

  • Earnings Report: PASSAGE BIO, INC. reported a loss of $7.75 million for the third quarter, a significant improvement from a loss of $19.34 million in the same period last year.

  • Earnings Per Share: The company's earnings per share (EPS) was -$2.44, compared to -$6.15 in the previous year, indicating a positive trend.

  • Analyst Expectations: The reported loss was better than analysts' expectations, who had predicted an EPS of -$2.97.

  • General Information: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

[object Object]
Preview
9.5
11-11Newsfilter
Passage Bio Announces Financial Results for Q3 2025 and Shares Recent Business Updates

  • Clinical Trial Enrollment: Passage Bio is actively enrolling patients in Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) for its upliFT-D clinical trial, which aims to evaluate the safety and efficacy of PBFT02 in treating frontotemporal dementia.

  • FDA Alignment: The company has successfully aligned with the FDA on an analytical plan to establish comparability for its high-productivity PBFT02 manufacturing process, which is expected to enhance productivity and purity.

  • Regulatory Feedback Timeline: Passage Bio is on track to receive regulatory feedback on the trial design for FTD-GRN in the first half of 2026, with plans to report interim safety and biomarker data from Dose 2 around the same time.

  • Financial Overview: As of September 30, 2025, Passage Bio reported a cash position of $52.8 million, which is expected to fund operations into the first quarter of 2027, alongside a reduced net loss compared to the previous year.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Passage Bio Inc (PASG) stock price today?

The current price of PASG is 9.183 USD — it has increased 6.9 % in the last trading day.

arrow icon

What is Passage Bio Inc (PASG)'s business?

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

arrow icon

What is the price predicton of PASG Stock?

Wall Street analysts forecast PASG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PASG is 40.33 USD with a low forecast of 21.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Passage Bio Inc (PASG)'s revenue for the last quarter?

Passage Bio Inc revenue for the last quarter amounts to -8.66M USD, decreased -45.59 % YoY.

arrow icon

What is Passage Bio Inc (PASG)'s earnings per share (EPS) for the last quarter?

Passage Bio Inc. EPS for the last quarter amounts to -4853000.00 USD, decreased -35.01 % YoY.

arrow icon

What changes have occurred in the market's expectations for Passage Bio Inc (PASG)'s fundamentals?

The market is revising No Change the revenue expectations for Passage Bio, Inc. (PASG) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 27.90%.
arrow icon

How many employees does Passage Bio Inc (PASG). have?

Passage Bio Inc (PASG) has 60 emplpoyees as of December 05 2025.

arrow icon

What is Passage Bio Inc (PASG) market cap?

Today PASG has the market capitalization of 29.02M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free